Monitor for topline data releases by mid-August 2026; positive results would be a major catalyst for MPLT, while negative results could significantly impact the stock. Consider positioning ahead of the data readout.
Price Chart
Executive Summary
MapLight Therapeutics announced completion of enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia (307 participants) and the last patient visit in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder (161 participants). Topline results from both trials are expected by mid-August 2026, representing key catalysts for the stock.
Key Facts
- Enrollment completed in ZEPHYR Phase 2 trial for ML-007C-MA in schizophrenia with 307 participants randomized 1:1:1 to placebo or two doses.
- Last patient visit completed in IRIS Phase 2 trial for ML-004 in autism spectrum disorder with 161 participants randomized.
- Topline results from both Phase 2 trials expected by mid-August 2026.
Financial Impact
Not specified
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data.
- Regulatory delays or unfavorable risk-benefit profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285832 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Insider Cluster | $8.00 | awaiting T+20 | — | $7.66 (+4.25%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.66 (−0.52%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.66 (−0.52%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.66 (−0.52%) |
Sep 24, 2026 4w ago | EFFECT | $10.76 $8.25 | ▼ −23.33% | ▼ −22.91% | $7.66 (−28.81%) |
Sep 18, 2026 5w ago | S-1/A | $10.90 $8.00 | ▼ −26.61% | ▼ −25.70% | $7.66 (−29.72%) |
Aug 4, 2026 11w ago | Insider Cluster | $12.92 $13.06 | ▲ +1.08% | ▲ +1.69% | $7.66 (−40.71%) |
Aug 3, 2026 12w ago | 144 | $12.94 $13.31 | ▲ +2.86% | ▲ +4.10% | $7.66 (−40.80%) |
Jul 30, 2026 12w ago | 144 | $13.02 $12.60 | ▲ +3.23% | ▲ +6.21% | $7.66 (+41.17%) |
Jul 28, 2026 12w ago | Insider Buy | $15.02 $12.86 | ▼ −14.38% | ▼ −19.40% | $7.66 (−49.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers